ROG

Ad hoc announcement pursuant to Art. 53 LR Basel, 22 October 2026 Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine months of 2026 - Group sales were +6% at constant exchange rates (CER)1, +1% when reported in CHF and +7% in USD2, in the first nine months of 2026, driven by high demand for our innovative medicines and diagnostics. In the third quarter, sales grew +7% (CER) and +8% in CHF (+7% in USD), as exchange rates stabilised. - Pharmaceuticals Division sales were +7% at CER, +2% when reported in CHF and +8% in USD, in the first nine months, due to continued high demand for medicines to treat severe diseases; Xolair (chronic hives, food allergies), Hemlibra (haemophilia A), Ocrevus (multiple sclerosis), Phesgo (breast cancer) and Vabysmo (severe eye diseases) were the top growth drivers. - Diagnostics Division sales were +4% at CER, stable when reported in CHF and +6% in USD, in the first nine months, as demand for core lab and pathology solutions more than offset the impact of healthcare pricing reforms in China. - Highlights: - US approval for Tecentriq for the adjuvant treatment of stage-III DNA mismatch repair colon cancer, Gazyva/Gazyvaro for reducing the risk of relapse in patients 2 years of age and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome and Enspryng in thyroid eye disease - US Priority Reviews for fenebrutinib in both relapsing and primary progressive multiple sclerosis and Enspryng in MOGAD, an autoimmune disease; vamikibart filing acceptance in uveitic macular edema, a leading cause of vision loss - EU approval for Susvimo in neovascular age-related macular degeneration (nAMD), a severe eye disease, and Ocrevus in paediatric relapsing multiple sclerosis; EMA validation of application for Enspryng in MOGAD in Europe - - Positive data for: sefaxersen in an autoimmune condition affecting kidney function (phase III), Lunsumio in blood cancer (phase III), Tam-Peli in relapsed small-cell lung cancer (phase III) as well as enicepatide and petrelintide in overweight or obesity and type 2 diabetes (both phase II) - US clearance for Elecsys pTau217 test, providing clinicians across primary and specialty care with a single-biomarker blood test to aid in identifying amyloid pathology associated with Alzheimer's disease - Launch of two new, real-time PCR tests to support public health epidemic response to the US outbreak of the Cyclospora cayetanensis parasite - Delivery of molecular tests to support the Democratic Republic of the Congo health ministry-led response to the Ebola outbreak - Manufacturing and R&D capacity expansion: Hillsboro injectable medicines facility and Innovation Center Boston for cardiovascular, renal and metabolic diseases in the US and small molecules facility in Basel, Switzerland - Outlook for 2026 confirmed Roche CEO Thomas Schinecker: "In the third quarter, we delivered strong sales growth of +7% at constant exchange rates and +8% in Swiss francs. Most importantly, we continued to make meaningful progress for patients. We advanced another five potential new medicines into the final stage of development this year and now aim to bring up to 20 new medicines to patients by 2030. The US FDA granted Priority Review for fenebrutinib in both relapsing and primary progressive multiple sclerosis, bringing us closer to delivering the first high-efficacy, brain-penetrant oral therapy to patients. Giredestrant is also under FDA Priority Review in both early-stage and advanced breast cancer, and we are fully prepared to launch later this year, pending approval. In Diagnostics, we received US FDA clearance for Elecsys pTau217, the first and only FDA-cleared single-biomarker blood test for Alzheimer's disease that supports both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings. We confirm our full-year outlook." Outlook for 2026 Roche (SIX: RO, ROP; OTCQX: RHHBY) expects an increase in Group sales in the mid single digit range (CER) for 2026. Core earnings per share are targeted to develop in the high single digit range (CER). Roche expects to further increase its dividend in Swiss francs. Sales | CHF millions | As % of sales | % change January–September | 2026 | 2025 | 2026 | 2025 | At CER | In CHF | In USD Group | 46,493 | 45,862 | 100.0 | 100.0 | +6 | +1 | +7 | | | | | | | Pharmaceuticals Division | 36,212 | 35,555 | 77.9 | 77.5 | +7 | +2 | +8 United States | 18,712 | 18,798 | 40.2 | 41.0 | +5 | 0 | Europe | 6,819 | 6,818 | 14.7 | 14.9 | +2 | 0 | Japan | 2,352 | 2,139 | 5.1 | 4.7 | +25 | +10 | International | 8,329 | 7,800 | 17.9 | 16.9 | +10 | +7 | | | | | | | | Diagnostics Division | 10,281 | 10,307 | 22.1 | 22.5 | +4 | 0 | +6 International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others Group sales In the first nine months of 2026, Roche sales were +6% at CER, +1% when reported in CHF, to CHF 46.5 billion due to strong demand for pharmaceutical products and diagnostic solutions. The appreciation of the Swiss franc against most currencies, notably the US dollar, had a significant impact on the results reported in Swiss francs compared to constant exchange rates. This currency impact reversed in the third quarter. Sales growth in the Pharmaceuticals Division was +7% at CER, +2% when reported in CHF, to CHF 36.2 billion, with medicines for severe diseases continuing their strong growth. The top five growth drivers – Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo – achieved total sales of CHF 16.8 billion, an increase of +12% at CER, or +6% in CHF, compared to the first nine months of 2025. Sales of products with expired patents (Avastin, Herceptin, MabThera/Rituxan, Lucentis and Actemra/RoActemra) decreased by a combined CHF 0.4 billion at CER, or CHF 0.6 billion in CHF. In the United States, sales were +5% at CER, stable when reported in CHF, due to continued growth of Xolair, Hemlibra, Ocrevus, Polivy (blood cancer) and Tecentriq (cancer immunotherapy). This growth more than compensated for the lower sales of Kadcyla (breast cancer) and Perjeta (breast cancer). Sales in Europe were +2% at CER, stable when reported in CHF, as the growing demand for Ocrevus, Phesgo and Evrysdi (spinal muscular atrophy) more than offset the impact of biosimilar competition on Actemra/RoActemra and the conversion to Phesgo on Perjeta. In Japan, sales were +25% at CER, +10% when reported in CHF, mainly due to product supply to third parties and continued growth of Lunsumio (blood cancer), Hemlibra, Polivy, Elevidys (Duchenne muscular dystrophy) and Vabysmo. There was also a positive impact of timing effects related to the implementation of a new enterprise resource planning (ERP) system. Sales in the International region were +10% at CER, +7% when reported in CHF, led by higher sales of Phesgo, Vabysmo, Hemlibra, Ocrevus and Evrysdi. In China, sales were stable at CER and when reported in CHF, driven by continued growth of Phesgo, Vabysmo, Alecensa and Polivy. The increase was partially offset by lower sales of Perjeta due to the conversion to Phesgo and Xofluza due to a milder flu season in 2025. The Diagnostics Division's sales were +4% at CER, stable when reported in CHF, to CHF 10.3 billion as growth in demand for core lab and pathology solutions more than offset the impact of healthcare pricing reforms in China. Sales in the Europe, Middle East and Africa (EMEA) region were +3% at CER, unchanged when reported in CHF, driven by higher sales of clinical chemistry and immunodiagnostic products. In North America, sales were +9% at CER, +3% when reported in CHF, with growth across the Core Lab, Pathology Lab and Molecular Lab customer areas. Sales in Asia-Pacific were -4% at CER, or -8% when reported in CHF, due to the healthcare pricing reforms in China. In Latin America, sales growth was +12% at CER, or +11% when reported in CHF. Pharmaceuticals: key developments Compound | Milestone Regulatory Enspryng Thyroid eye disease | FDA approves Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)FDA approval based on phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favourable safety profile, regardless of TED activity or duration.Enspryng (satralizumab) represents an important advance for people with TED, offering the first at-home subcutaneous treatment option every four weeks during maintenance phase, allowing for greater flexibility in how treatment is administered.Enspryng is an anti-IL-6R monoclonal antibody using novel recycling antibody technology designed to inhibit IL-6 signalling upstream of autoantibody-driven pathology.TED is a rare autoimmune disease affecting approximately 155 out of every 100,000 people in the US that can lead to facial disfigurement and vision-threatening complications if left untreated.More information: Media Release, 16 October 2026 Tecentriq Different types of cancer | FDA approves Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancerThe approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone.It is the first approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, positioning Tecentriq as a new post-surgery standard of care.Nearly 25% of all colon cancers are diagnosed at stage III, and almost one in three patients with stage III colon cancer experience a recurrence within five years.Approval marks the twelfth indication for Tecentriq in the US.More information: Media Release, 9 October 2026 Fenebrutinib Multiple sclerosis | Fenebrutinib is the first BTK inhibitor to receive US FDA filing acceptance in both relapsing and primary progressive multiple sclerosisFenebrutinib cut relapses by 51% and 58% vs teriflunomide in phase III RMS trials (FENhance 1 and 2) while showing a consistent, positive trend in delaying disability.Fenebrutinib became the first investigational medicine in more than a decade to slow disability progression in a phase III PPMS trial (FENtrepid), with numerical benefit vs Ocrevus.Fenebrutinib is designed to address two drivers of MS – acute inflammation causing relapses and chronic brain inflammation driving disability progression.If approved, fenebrutinib would become the first BTK inhibitor and first high-efficacy oral treatment for both RMS and PPMS, offering a new option for the nearly 1 million people living with MS in the US.More information: Media Release, 30 September 2026 Susvimo Severe eye diseases | European Commission approves Susvimo for the treatment of neovascular age-related macular degeneration By continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is the first and only continuous delivery treatment that offers an alternative to standard-of-care eye injections for nAMD.Susvimo helps people with nAMD maintain their vision with as few as two treatments per year.Data from the phase III Archway study showed that Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections.nAMD is a leading cause of vision loss in adults over 60 and affects approximately 1.7 million people across the European Union.More information: Media Release, 21 September 2026 Enspryng MOGAD | FDA grants Priority Review for Enspryng for MOGAD, an autoimmune disease with no approved treatmentsIf approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease).The filing acceptance is based on the phase III METEOROID study showing that Enspryng reduced the risk of relapses by 68%.The European Medicines Agency (EMA) has validated the application for Enspryng for MOGAD in Europe, with a decision expected in Q3 2027.More information: Media Release, 10 September 2026 Phase III, pivotal and other key read-outs Sefaxersen IgA nephropathy | Positive interim data shows sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN) In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential.Sefaxersen inhibits complement factor B production at its primary source in the liver, thus blocking a key driver of IgAN-related kidney damage.Interim data will be presented at an upcoming medical meeting and shared with health authorities.More information: Media Release, 23 September 2026 Enicepatide Obesity | Roche announces positive phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesityAt the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycaemic control.By week 48, 90% of patients in the 24 mg enicepatide arm met the type-2-diabetes glycaemic target of ≤6.5% HbA1c, while 62% achieved normoglycaemia (HbA1c <5.7%).At the highest 24 mg dose, enicepatide achieved a mean weight loss of 15.5% at 48 weeks, without a weight loss plateau.More information: Media Release, 22 September 2026 Lunsumio Blood cancer | Regimen based on Lunsumio significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO studyPhase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular lymphoma who have received at least one prior line of treatment.Data reinforce the potential of this regimen based on Lunsumio to improve clinical outcomes, while offering a tolerable safety profile, a simple dosing schedule and outpatient administration.CELESTIMO is the confirmatory study required to convert the accelerated approval / conditional marketing authorisation of Lunsumio monotherapy for third-line or later (3L+) follicular lymphoma to full approval, as well as to secure an indication in second-line or later (2L+) follicular lymphoma.Data will be submitted to health authorities and presented at an upcoming medical meeting.More information: Media Release, 17 September 2026 Tam-Peli Lung cancer | Roche's collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancerTambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7%.The novel B7-H3-targeted antibody-drug conjugate with a dual release mechanism of the payload is based on MediLink's proprietary TMALIN platform, designed to maximise antitumour activity while minimising off-target toxicity.Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau across multiple tumour types, with plans to rapidly initiate global trials. Tam-Peli has received US FDA and China CDE Breakthrough Therapy Designations for relapsed small-cell lung cancer.More information: Media Release, 13 September 2026 Vabysmo Severe eye diseases | Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of nAMD The SALWEEN study showed significant improvements in vision and retinal health.More than 60% of Asian patients with polypoidal choroidal vasculopathy (PCV), an aggressive subtype of nAMD, treated with Vabysmo showed no signs of polypoidal lesions.By the end of year two, more than 60% of patients were on an extended 20-week treatment interval, reducing treatment burden. More information: Media Release, 28 August 2026 Other ESMO presentation Lung and breast cancer portfolio | Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolioPhase III Krascendo 1 results demonstrated divarasib's superiority over current standard-of-care, first-generation KRAS G12C inhibitors in previously treated advanced G12C-mutated non-small cell lung cancer.Patient-reported outcomes from phase III lidERA study showed that improved efficacy of giredestrant over standard endocrine therapy is achieved without compromising tolerability and health-related quality of life in early-stage breast cancer.Phase III results in Chinese patients with metastatic nasopharyngeal carcinoma demonstrate the potential of Tam-Peli, a next-generation B7-H3-targeted ADC, to deliver robust efficacy with a favourable safety profile in high-unmet-need solid tumours.More information: Media Release, 19 October 2026 Vamikibart Uveitic macular edema | Roche presents new phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision lossIn the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks.UME is the leading cause of moderate and severe vision loss in patients with uveitis, posing a significant risk of blindness if left untreated.The FDA has accepted Roche's Biologics License Application (BLA), with an approval decision expected by July 2027.More information: Media Release, 10 October 2026 Vabysmo Severe eye diseases | Roche presents new data at EURETINA, highlighting the real-world effectiveness and safety of Vabysmo across major retinal conditionsNew real-world results for Vabysmo in nAMD, diabetic macular edema and retinal vein occlusion reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals.Advanced AI-enabled analysis of imaging confirms rapid and meaningful anatomical drying supporting Vabysmo as a standard-of-care therapy in routine clinical care.With more than 5,000 patients enrolled, VOYAGER is the largest, prospective, non-interventional real-world dataset evaluating Vabysmo across diverse clinical practice settings worldwide.More information: Media Release, 1 October 2026 Giredestrant Breast cancer | Giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of MedicineGiredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimus.By targeting resistance to endocrine treatments, the giredestrant combination seeks to delay disease progression and improve overall patient outcomes.The FDA has set a PDUFA goal date for giredestrant in early-stage breast cancer of 30 November 2026 and in advanced disease of 18 December 2026.More information: Media Release, 1 October 2026 Board of Directors nomination | Roche proposes Dr Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to its Board of Directors at the 2027 Annual General Meeting Roche's Board of Directors has approved to propose Dr Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board at the Annual General Meeting on 9 March 2027.Roche Chairman Severin Schwan highlighted Dr Weber's extensive healthcare industry knowledge and leadership experience as valuable assets for the Board.Roche continues its commitment to transformative medicines and diagnostics, focusing on major disease areas and global healthcare challenges.More information: Media Release, 23 September 2026 Innovation Center Boston | Roche announces grand opening of its Innovation Center Boston to drive advancements in cardiovascular, renal and metabolic diseasesThe centre will be a hub for Roche and Genentech, bringing together expertise in cardiovascular, renal and metabolic diseases, as well as for data science and AI specialists to drive innovation in drug discovery and development.It will expand Roche's and Genentech's presence in Boston, reflecting a long-term commitment to one of the world's leading life sciences hubs.This is part of Roche and Genentech's USD 50 billion investment in US manufacturing and R&D, building on recent investments and manufacturing milestones in Holly Springs, North Carolina, and Hillsboro, Oregon.More information: Media Release, 17 September 2026 Hillsboro facility | Genentech, Roche's US subsidiary, announces a USD 750 million manufacturing expansion in Hillsboro, OregonThe new facility in Hillsboro, Oregon for the assembly of injectable medicines and delivery devices will further advance end-to-end US drug manufacturing capabilities.Approximately USD 750 million investment will double the size of the existing facility and is expected to create an additional 250 specialised manufacturing jobs.Flexible manufacturing capacity will support advanced drug delivery devices that can provide patients with more convenient ways to receive treatment.More information: Media Release, 20 August 2026 Pharmaceuticals sales Sales | CHF millions | As % of sales | % change January–September | 2026 | 2025 | 2026 | 2025 | At CER | In CHF Pharmaceuticals Division | 36,212 | 35,555 | 100.0 | 100.0 | +7 | +2 United States | 18,712 | 18,798 | 51.7 | 52.9 | +5 | 0 Europe | 6,819 | 6,818 | 18.8 | 19.2 | +2 | 0 Japan | 2,352 | 2,139 | 6.5 | 6.0 | +25 | +10 International | 8,329 | 7,800 | 23.0 | 21.9 | +10 | +7 International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others Top 20 best-selling pharmaceuticals (% change at CER1) | Total | United States | Europe | Japan | International CHF m | % | CHF m | % | CHF m | % | CHF m | % | CHF m | % Ocrevus Multiple sclerosis | 5,317 | +7 | 3,581 | +5 | 1,136 | +9 | - | - | 600 | +21 Hemlibra Haemophilia A | 3,750 | +12 | 2,006 | +9 | 769 | +5 | 291 | +20 | 684 | +23 Vabysmo Eye diseases (nAMD, DME, RVO) | 3,196 | +10 | 2,060 | +2 | 585 | +7 | 131 | +41 | 420 | +65 Tecentriq Cancer immunotherapy | 2,615 | +5 | 1,243 | +8 | 626 | -2 | 245 | +6 | 501 | +9 Xolair3 Chronic hives, food allergies | 2,521 | +20 | 2,521 | +20 | - | - | - | - | - | - Phesgo Breast cancer | 2,064 | +18 | 486 | -1 | 657 | +11 | 152 | +24 | 769 | +43 Perjeta3 Breast cancer | 2,040 | -8 | 824 | -10 | 361 | -13 | 38 | -20 | 817 | -3 Actemra/RoActemra3 RA, COVID-19 | 1,621 | -10 | 795 | -9 | 328 | -26 | 232 | +14 | 266 | -4 Evrysdi Spinal muscular atrophy | 1,470 | +18 | 497 | +12 | 504 | +14 | 65 | +7 | 404 | +33 Kadcyla3 Breast cancer | 1,339 | -9 | 442 | -19 | 370 | -5 | 65 | +9 | 462 | -2 Polivy Blood cancer | 1,302 | +24 | 606 | +29 | 204 | -9 | 176 | +30 | 316 | +44 Alecensa Lung cancer | 1,213 | +6 | 391 | -1 | 189 | -3 | 154 | +15 | 479 | +15 MabThera/Rituxan3 Blood cancer, RA | 919 | +3 | 605 | +12 | 94 | -8 | 8 | -16 | 212 | -10 Activase/TNKase3 Cardiac diseases | 830 | +6 | 792 | +5 | - | - | - | - | 38 | +12 Gazyva/Gazyvaro3 Blood cancer, lupus nephritis | 751 | +7 | 369 | +4 | 176 | -2 | 28 | +28 | 178 | +25 Herceptin3 Breast and gastric cancer | 695 | -12 | 140 | -15 | 205 | -6 | 3 | -35 | 347 | -13 Avastin3 Various cancer types | 639 | -12 | 195 | -8 | 56 | +5 | 56 | -43 | 332 | -9 Columvi Blood cancer | 327 | +67 | 146 | +24 | 92 | +113 | - | - | 89 | +167 Enspryng Acute inflammation of brain, spinal cord and optic nerves | 319 | +28 | 79 | +18 | 34 | +18 | 138 | +30 | 68 | +42 Pulmozyme3 Cystic fibrosis | 303 | -12 | 214 | -11 | 43 | -11 | 1 | +38 | 45 | -18 DME: diabetic macular edema / nAMD: neovascular or 'wet' age-related macular degeneration / RVO: retinal vein occlusion / RA: rheumatoid arthritis Diagnostics key developments Product | Milestone Elecsys pTau217 Alzheimer's disease | Roche receives FDA clearance for Elecsys pTau217, advancing Alzheimer's disease assessment across primary and specialty careIt is the first and only FDA-cleared, single-biomarker blood test supporting both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings.The test delivers consistency across clinical settings by using the same validated cut-offs in primary and specialty care.It is designed for broad implementation across Roche's installed base of more than 4,500 cobas laboratory instruments in the US supporting access through existing laboratory infrastructure.More information: Investor Update, 24 August 2026 Diagnostics sales Sales | CHF millions | As % of sales | % change January–September | 2026 | 2025 | 2026 | 2025 | At CER | In CHF Diagnostics Division | 10,281 | 10,307 | 100.0 | 100.0 | +4 | 0 Customer areas | | | | | | Core Lab | 5,755 | 5,688 | 56.0 | 55.2 | +5 | +1 Molecular Lab | 1,836 | 1,861 | 17.9 | 18.1 | +3 | -1 Near Patient Care | 1,348 | 1,477 | 13.1 | 14.3 | -5 | -9 Pathology Lab | 1,342 | 1,281 | 13.0 | 12.4 | +10 | +5 Regions | | | | | | Europe, Middle East, Africa | 3,698 | 3,686 | 36.0 | 35.8 | +3 | 0 North America | 3,389 | 3,305 | 32.9 | 32.1 | +9 | +3 Asia-Pacific | 2,343 | 2,547 | 22.8 | 24.7 | -4 | -8 Latin America | 851 | 769 | 8.3 | 7.4 | +12 | +11 More information on Roche's performance in the first nine months of 2026: - 9M 2026 presentation - Appendix with tables About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceuticals Divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] CER (Constant Exchange Rates). The percentage changes at constant exchange rates are calculated using simulations by reconsolidating both the 2026 and 2025 results at constant exchange rates (the average rates for the year ended 31 December 2025). For the definition of CER, see page 178 of the Roche Finance Report 2025. [2] USD (US dollars). The percentage changes for selected sales figures at US dollars are calculated by translating both the 2026 and 2025 sales figures at the respective average US dollar exchange rate for the period in question. This supplementary information is provided to assist readers when assessing comparability with other companies. [3] Products launched before 2015. Cautionary statement regarding forward-looking statements This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, such as: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for this or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: [email protected] Tristan Schmitz Phone: +41 79 529 70 35 | Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915 | Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53 | Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan Phone: +41 79 377 83 75 | Albert Thottiyil Phone: +41 79 775 66 12 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 687 5 284 e-mail: [email protected] | Dr Sabine Borngräber Phone: +41 61 688 80 27 e-mail: [email protected] Dr Birgit Masjost Phone: +41 61 688 48 14 e-mail: [email protected] | Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: [email protected] | Attachments - Communications appendix tables_YTD Sep 2026_Sales_02102026 - Media Investor Release Roche Q3 2026 English

At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycemic control In patients with poor baseline glycemic control (HbA1c >8.5%), enicepatide 24 mg led to an HbA1c reduction of 4.13% at 48 weeks By week 48, 90% of patients in the 24 mg enicepatide arm met the T2D glycemic target of ≤6.5% HbA1c, while 62% achieved normoglycemia (HbA1c At the highest 24 mg dose, enicepatide achieved a mean weight loss of 15.5% at 48 weeks, without a weight loss plateau Enicepatide demonstrated a safety and tolerability profile consistent with the incretin class, with low discontinuation rates and no new safety signals identified Basel, 22 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) today announced positive topline results from CT-388-104, a Phase II clinical trial evaluating enicepatide (CT-388), an investigational, once-weekly dual GLP-1/GIP receptor agonist, in adults living with type 2 diabetes (T2D) and overweight or obesity. In the study, enicepatide met both primary endpoints, delivering dose-dependent and clinically meaningful reductions in blood glucose and body weight at 48 weeks. Patients receiving the highest titrated dose (24 mg) achieved an HbA1c reduction of 2.65% (from a baseline HbA1c of 8.1%). Furthermore, 90% of patients in the 24 mg cohort reached an HbA1c level of ≤6.5% (diagnostic threshold for T2D) and 62% achieved normoglycemia (HbA1c < 5.7%), restoring blood glucose levels to a non-diabetic range. The mean weight loss at 48 weeks in the 24 mg enicepatide arm was 15.5% without a demonstrable plateau. The safety and tolerability profile of enicepatide was consistent with other established incretin-based therapies, with the most common adverse events being predominantly mild-to-moderate gastrointestinal effects. In addition, the treatment discontinuation rate due to adverse events was low (2.0% in enicepatide arms; 0.0% in placebo arm). The totality of data positions enicepatide, a unique dually biased GLP-1/GIP receptor agonist, as a differentiated molecule designed for potentially greater efficacy with a favorable safety profile. “We are highly encouraged by the efficacy demonstrated by enicepatide in this Phase II study, including the meaningful proportion of patients reaching normalised glucose levels within less than a year of treatment,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Combined with sustained weight loss, enicepatide offers a potential best-in-disease profile capable of reducing and preventing complications as well as enhancing metabolic health for people living with type 2 diabetes.” Roche is advancing a broad late-stage development program for enicepatide, including two ongoing Phase III studies in chronic weight management (ENITH-1 and ENITH-2) and plans to initiate a Phase III glycemic-control program and cardiovascular outcomes trials in the first half of 2027. “These results reinforce our confidence in enicepatide and our ambition to rapidly advance its development for people living with obesity, diabetes, and cardiovascular disease,” said Teresa Graham, Chief Executive Officer, Roche Pharmaceuticals. “As we expand into late-stage clinical studies and explore novel combinations, we are leveraging our integrated diagnostic and therapeutic expertise to build a competitive cardiometabolic portfolio — aiming to protect people from early metabolic dysfunction to advanced organ damage, ultimately reducing the global disease burden.” About the enicepatide 104 Phase II study [NCT06628362]The CT-388-104 study is a randomized, double-blind, placebo-controlled, parallel-group, multi-center Phase II trial evaluating the efficacy, safety, and tolerability of once-weekly enicepatide administered subcutaneously for 48 weeks in 447 adults living with T2DM and overweight or obesity. The dual primary outcomes are changes from baseline in HbA1c and body weight at week 48. About enicepatideEnicepatide is an investigational once-weekly subcutaneous injectable, dually biased GLP-1/GIP receptor agonist in development for the treatment of obesity, type 2 diabetes, and additional cardiovascular indications. It aims to reduce appetite and regulate blood sugar by selectively targeting and activating both receptors which integrate nutrient-derived signals to control energy homeostasis. Enicepatide was designed to have potent activation of both GLP-1 and GIP receptors, but with minimal to no ß-arrestin recruitment on either receptor. This biased signalling significantly minimises receptor internalisation and consequent desensitisation, which is expected to lead to prolonged pharmacological activity. About Obesity and T2DObesity and Type 2 diabetes are among the most urgent global public health challenges. Prevalence continues to rise, driving significant morbidity, disability and premature death. Obesity is a major risk factor for T2D because excess body fat contributes significantly to insulin resistance and dysfunction of the cells that produce insulin. Consequently, people living with obesity are seven times more likely to develop T2D than those with a normal body mass index. Diabetes is a condition that now affects nearly 600 million adults worldwide with T2D representing approximately 90% of cases with incidence rising fastest in low- and middle-income countries. Behind these growing numbers are people impacted by not only the ongoing daily management of diabetes, but its complications as well, such as blindness, kidney failure, strokes and even amputations. One of the most serious health risks of diabetes is cardiovascular disease. People living with diabetes face a 2-4 times higher risk of hypertension, heart failure, stroke, and coronary artery disease than those without it. Prolonged high blood glucose silently damages blood vessels and nerves, making cardiovascular complications more likely, more frequent and more severe over time. HbA1c (glycated hemoglobin) is measuring the average blood glucose levels over the past two to three months. HbA1c of 6.5% represents the clinical threshold for diagnosing diabetes, whereas normoglycemia (HbA1c less than 5.7%) represents non-diabetic blood glucose levels. An HbA1c level between 5.7% and 6.4% defines the prediabetes range.About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law.Roche Global Media RelationsPhone: +41 61 688 8888 / e-mail: [email protected] Roche Investor Relations Investor Relations North America Attachment Ad-Hoc Media Investor Release CT-388-104 enicepatide English

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how electronic components & manufacturing stocks fared in Q2, starting with Rogers (NYSE:ROG). The sector could see higher demand as the prevalence of advanced electronics increases in industries such as automotive, healthcare, aerospace, and computing. The high-performance components and contract manufacturing expertise required for autonomous vehicles and cloud computing datacenters, for instance, will benefit companies in the space. However, headwinds include geopolitical risks, particularly U.S.-China trade tensions that could disrupt component sourcing and production as the Trump administration takes an increasingly antagonizing stance on foreign relations. Additionally, stringent environmental regulations on e-waste and emissions could force the industry to pivot in potentially costly ways. The 10 electronic components & manufacturing stocks we track reported an exceptional Q2. As a group, revenues beat analysts’ consensus estimates by 4% while next quarter’s revenue guidance was 6% above. While some electronic components & manufacturing stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 2.1% since the latest earnings results. With roots dating back to 1832, making it one of America's oldest continuously operating companies, Rogers (NYSE:ROG) designs and manufactures specialized engineered materials and components used in electric vehicles, telecommunications, renewable energy, and other high-performance applications. Rogers reported revenues of $216.8 million, up 6.9% year on year. This print exceeded analysts’ expectations by 0.8%. Despite the top-line beat, it was still a mixed quarter for the company with revenue guidance for next quarter exceeding analysts’ expectations but a significant miss of analysts’ EPS estimates. Rogers delivered the weakest performance against analyst estimates and slowest revenue growth among its peers. Interestingly, the stock is up 8.1% since reporting and currently trades at $128.79. Is now the time to buy Rogers? Access our full analysis of the earnings results here, it’s free. With over 90 years of connecting the world's technologies, Amphenol (NYSE:APH) designs and manufactures connectors, cables, sensors, and interconnect systems that enable electrical and electronic connections across virtually every industry. Amphenol reported revenues of $8.76 billion, up 55% year on year, outperforming analysts’ expectations by 5.6%. The business had an incredible quarter with a solid beat of analysts’ EPS guidance for next quarter estimates and revenue guidance for next quarter exceeding analysts’ expectations. Amphenol scored the fastest revenue growth in the group. The market seems happy with the results as the stock is up 16.2% since reporting. It currently trades at $83.56. Is now the time to buy Amphenol? Access our full analysis of the earnings results here, it’s free. With manufacturing facilities spanning the globe from China to Mexico to the United States, Jabil (NYSE:JBL) provides electronics design, manufacturing, and supply chain solutions to companies across various industries, from healthcare to automotive to cloud computing. Jabil reported revenues of $8.75 billion, up 11.8% year on year, exceeding analysts’ expectations by 2.3%. It may have had the worst quarter among its peers, but its results were still good as it also locked in a solid beat of analysts’ EPS guidance for next quarter estimates and revenue guidance for next quarter exceeding analysts’ expectations. As expected, the stock is down 17% since the results and currently trades at $311.85. Read our full analysis of Jabil’s results here. Operating as a critical behind-the-scenes partner for complex technology products since 1979, Benchmark Electronics (NYSE:BHE) provides advanced manufacturing, engineering, and technology solutions for original equipment manufacturers across aerospace, medical, industrial, and technology sectors. Benchmark reported revenues of $756 million, up 17.7% year on year. This print topped analysts’ expectations by 5%. It was a stunning quarter as it also produced a solid beat of analysts’ EPS guidance for next quarter estimates and revenue guidance for next quarter exceeding analysts’ expectations. The stock is flat since reporting and currently trades at $73.92. Read our full, actionable report on Benchmark here, it’s free. As one of the world's largest printed circuit board manufacturers with facilities spanning North America and Asia, TTM Technologies (NASDAQ:TTMI) manufactures printed circuit boards (PCBs) and radio frequency (RF) components for aerospace, defense, automotive, and telecommunications industries. TTM Technologies reported revenues of $1.00 billion, up 37.4% year on year. This result beat analysts’ expectations by 4.8%. Overall, it was a stunning quarter as it also logged an impressive beat of analysts’ EPS guidance for next quarter estimates and revenue guidance for next quarter exceeding analysts’ expectations. TTM Technologies pulled off the highest guidance raise of the whole group. The stock is flat since reporting and currently trades at $130.23. Read our full, actionable report on TTM Technologies here, it’s free. Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership. Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products. By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals. Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Rogers stock has delivered a strong 83.8% return over the past year, yet its valuation checks and earnings multiples suggest the shares are not obviously cheap at current levels. The 83.8% gain over the last 12 months raises the risk that recent enthusiasm is already reflected in the price. Recent revenue growth and improved profitability can support investor confidence in the business. However, any setback in customer demand or margins may weigh heavily on what looks like a full valuation. Rogers scores 2 of 6 on Simply Wall St's valuation checks, which leans expensive rather than a clear bargain on the broader metrics, as seen in the valuation summary. The issue now is whether the current share price already captures the recent improvements in Rogers' performance or still leaves room for further upside. Rogers delivered 83.8% returns over the last year. See how this stacks up to the rest of the Electronic industry. For Rogers, the P/E ratio is a useful yardstick because the company is already profitable and investors often anchor on earnings for a business like this. The stock trades on about 73.3x earnings, which is more than double the Electronic industry average of roughly 31.2x and only slightly below a peer group average of about 76.6x. That places Rogers at the higher end of the sector on this measure. The fair P/E ratio from the model is about 37.7x, which is roughly half of where Rogers trades today. The recent second quarter 2026 update points to solid revenue and adjusted earnings progress. However, the current valuation already assumes a lot of good news when set against this more tailored benchmark. Investors are paying a significant premium compared with what the model suggests would be a more typical earnings multiple for the company. On the P/E multiple, Rogers stock currently screens as overvalued relative to both its industry and the modelled fair ratio. See what the numbers say about this price — find out in our valuation breakdown. Simply Wall St Narratives for Rogers pick up where the valuation puzzle leaves off by spelling out the kind of future on growth, margins and earnings that would need to play out for Rogers' stock to be worth materially more or less than today. Instead of stopping at a single valuation figure, these narratives unpack the assumptions behind that number so you can see what it implies and monitor whether the business is moving in that direction over time on the Community page. One of the top community narratives on Rogers: 14% undervalued Read one of the top narratives on Rogers Do you think there's more to the story for Rogers? Head over to our Community to see what others are saying! Rogers now trades on earnings multiples that screen as clearly overvalued relative to both its industry and the tailored fair ratio discussed above. The market is already assigning a premium that leaves limited room for disappointment if the story around earnings or margins weakens. For you as an investor, the key question is whether Rogers can deliver the kind of sustained execution that keeps justifying this higher P/E. The main point of debate is whether earnings quality and growth can keep pace with the expectations now embedded in the share price. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ROG. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Rogers (ROG) is back on investors radar after second quarter 2026 results showed year over year growth in sales and net income, alongside fresh revenue guidance that points to higher expectations for the third quarter. See our latest analysis for Rogers. The earnings rebound and new guidance have come alongside a sharp move in Rogers' stock, with a 1-day share price return of 5.18% and a year to date share price return of 46.85%. The 1-year total shareholder return of 80.44% contrasts with weaker 3 and 5 year total shareholder returns, suggesting recent momentum is building off a much tougher longer term record. If the Rogers update has you thinking about where else the market is rewarding improving stories, this is a good moment to scan 19 top founder-led companies After that sharp move in Rogers stock and a wide gap between the current US$135.06 share price and analyst value estimates around US$173, the next step is simple: Where does a reasonable view of fair value actually land? The most followed narrative sees fair value for Rogers at $183.33, well above the last close at $135.06, and builds that gap around a specific long term earnings path and profit profile. Read the complete narrative. Read the complete narrative. Want to see what underpins that valuation gap for Rogers? The whole story rests on compounding earnings, wider margins, and a richer future earnings multiple. Curious which assumptions really carry the weight? Result: Fair Value of $183.33 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Rogers still faces pressure from intense Asian competition in EV power substrates, as well as the risk that restructuring efforts do not deliver the planned cost savings. Find out about the key risks to this Rogers narrative. While the analyst narrative sees Rogers as 26.3% undervalued at $183.33, the current P/E of 77.1x tells a very different story. It sits well above the US Electronic industry at 31.2x and the fair ratio of 37.4x, which points to meaningful valuation risk if expectations ease. For a closer look at how those ratios line up with earnings quality and future expectations, See what the numbers say about this price — find out in our valuation breakdown. Mixed signals around Rogers and its valuation story can create strong opinions on both sides of the trade, so this is a useful time to review the full risk and reward balance for yourself. To weigh those views side by side and decide where you stand, start with the 3 key rewards and 1 important warning sign. If Rogers has sharpened your focus on quality and timing, do not stop here. Broaden your watchlist now or you may miss the next opportunity. Target stronger value opportunities by checking companies that screen as high quality and potentially mispriced through the 51 high quality undervalued stocks. Prioritise resilience and sleep-at-night positions by reviewing the 83 resilient stocks with low risk scores that flags stocks with sturdier risk profiles. Spot potential future leaders early by scanning the screener containing 21 high quality undiscovered gems that highlight lesser known companies with solid fundamentals. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ROG. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Interested in Rogers Corporation? Here are five stocks we like better. Rogers delivered strong second-quarter results: Sales rose 6.9% year over year to $216.8 million, while adjusted EBITDA increased to $37.6 million and adjusted EPS surged 171% to $0.92. Growth was led by industrial, electronics and communications, with automotive also posting modest gains. Supply-chain disruptions and a facility incident pressured earnings: Raw-material shortages, freight delays, higher operating expenses and a temporary factory shutdown reduced second-quarter earnings by more than $0.10 per share, although the facility issue has been resolved. The company expects broad growth in the third quarter: Rogers forecast revenue of $233 million to $243 million, adjusted EBITDA of $44 million to $50 million and adjusted EPS of $1.10 to $1.30. Management expects strength in aerospace and defense and general industrial markets, supported by higher volumes and restructuring savings despite commodity-cost and factory-underutilization headwinds. Rogers (NYSE:ROG) reported second-quarter 2026 sales growth and substantially higher profitability, while outlining a third-quarter outlook that calls for revenue growth across each of its major end markets. Second-quarter sales totaled $216.8 million, up 6.9% from a year earlier and above the midpoint of the company’s guidance range. President and CEO Ali El-Haj said the top-line performance reflected improving demand and market-share gains. → Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit Adjusted EBITDA increased to $37.6 million, or 17.3% of sales, compared with $23.9 million in the prior-year period. Adjusted earnings per share rose 171% year over year to $0.92. Gross margin reached 32.5%, improving 90 basis points from the second quarter of 2025. “We delivered another quarter of solid progress as our commercial and profitability initiatives continue to gain traction across all business units,” El-Haj said. → This Tiny AI Supplier Could Be More Important Than the Chipmakers Although the company’s adjusted EPS was within its guidance range, it fell below the midpoint due to supply-chain pressures, a one-time facility event and higher operating expenses. Chief Financial Officer Laura Russell said the combined impact of those factors exceeded $0.10 per share. El-Haj said Rogers continues to encounter shortages of certain raw materials, including silver and copper, as well as extended freight lead times related to conditions in the Middle East. Transit times that had historically ranged from four to six weeks have extended to more than 12 weeks in some cases, he said. → 2 Stocks Built to Thrive If Inflation Refuses to Fade Rogers also experienced a small fire at one facility that suspended manufacturing for several days and required cleanup work. El-Haj said the issue has been resolved and no employees were injured. Russell later said raw-material and freight headwinds, together with operating-expense timing and investments, represented roughly 70% to 80% of the second-quarter earnings impact. The balance was associated with the facility event. Industrial remained Rogers’ largest end market, accounting for about 37% of year-to-date sales. Revenue in the segment grew at a high single-digit rate from the prior-year quarter, supported by improving general industrial demand in the U.S. and Europe, particularly in the company’s silicone solutions business. Mass-transit demand was also strong, led by U.S. rail applications. Automotive represented about 25% of quarterly sales and grew at a low single-digit rate year over year. Sales of advanced driver-assistance systems and internal-combustion-engine vehicle applications increased. Electric-vehicle revenue was flat from a year earlier, as better power-substrate sales offset lower orders for EV battery materials. El-Haj said EV and hybrid-electric battery sales improved sequentially, and recent design wins are expected to support stronger EV sales in the second half as new programs ramp. Electronics and communications, which accounted for about 18% of sales, posted double-digit revenue growth. The performance was driven by wireless-infrastructure and smartphone demand, with smartphone sales benefiting from higher-end device mix and customer share gains. Aerospace and defense represented 15% of revenue and declined slightly year over year. Defense sales were lower because of customer ordering variability, though commercial aerospace demand improved. El-Haj said defense revenue is expected to improve significantly in the second half, while commercial aerospace demand remains strong. For the third quarter, Rogers forecast revenue of $233 million to $243 million. At the midpoint, the outlook represents 10% year-over-year growth. The company expects all four major end markets to grow, with particular strength anticipated in aerospace and defense and general industrial. Gross margin is expected to range from 33.2% to 34.2%. Adjusted EPS is forecast at $1.10 to $1.30. Adjusted EBITDA is projected at $44 million to $50 million. The midpoint of EBITDA guidance implies a 19.7% margin, up 250 basis points from the third quarter of 2025. Russell said third-quarter gross margin will be affected by underutilization at the company’s newer ceramic factory in China, which is expected to create an approximately 85-basis-point headwind. Commodity costs are also expected to remain a pressure. However, Rogers expects higher volume and cost-structure improvement actions to support margins. The company is working on supply contracts, copper sourcing and engineering initiatives intended to reduce material consumption. Russell said the company may pass through certain incremental commodity costs to customers in some situations, though such pricing changes can lag cost increases. The company also said its $13 million restructuring program involving the ceramic facility remains on track, with some savings already appearing in results. Rogers ended the second quarter with more than $211 million in cash and short-term investments, up $15.6 million from the end of the first quarter. Operating cash flow was $24.4 million, while free cash flow was $18.3 million. Capital expenditures were $6.1 million during the quarter, and the company expects full-year capital spending of $30 million to $35 million. The company repurchased $3 million of shares during the quarter, partially offsetting dilution from annual share issuances. Russell said Rogers intends to balance shareholder returns with other capital-allocation priorities and cited the company’s balance sheet as a source of strategic flexibility. El-Haj said testing and validation of Rogers’ microchannel cooler technology for high-power artificial intelligence and data-center applications continued with multiple customers. The company is also sampling high-frequency circuit materials for data-center uses with prospective customers, with initial feedback described as positive. Rogers plans to provide more details on its strategy, growth opportunities, innovation programs, capital-allocation priorities and long-term financial planning at an analyst and investor day in New York City on Sept. 30, 2026. Rogers Corporation (NYSE: ROG) is a global technology and materials company specializing in the development and manufacture of engineered materials and components. The company designs and produces a broad portfolio of high-performance elastomeric, foam, silicone, adhesive and thermal management solutions, as well as advanced circuit board laminates. Its products are engineered to meet stringent requirements in areas such as electrical insulation, thermal performance and electromagnetic shielding. Rogers serves a diverse range of end markets, including automotive, aerospace and defense, telecommunications, consumer electronics and industrial applications. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Rogers Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for July 2026.

This article first appeared on GuruFocus. Revenue: $216.8 million, up 6.9% from the prior year. Adjusted EBITDA: $37.6 million, or 17.3% of sales, a 550 basis point increase year over year. Adjusted EPS: $0.92, up 171% from the second quarter of 2025. Gross Margin: 32.5%, up 90 basis points year over year. Cash and Short-term Investments: Exceeded $211 million, an increase of $15.6 million from Q1 2026. Free Cash Flow: $18.3 million. Capital Expenditures: $6.1 million in Q2; full-year 2026 expected range between $30 million and $35 million. Q3 Revenue Guidance: $233 million to $243 million, a 10% increase year over year at the midpoint. Q3 Gross Margin Guidance: 33.2%-34.2%, with a 20 basis point increase at the midpoint compared to the prior year. Q3 Adjusted EPS Guidance: $1.10-$1.30, with a midpoint of $1.20. Q3 Adjusted EBITDA Guidance: $44 million-$50 million, equating to a 19.7% EBITDA margin at the midpoint. Warning! GuruFocus has detected 5 Warning Signs with ROG. Is ROG fairly valued? Test your thesis with our free DCF calculator. Release Date: July 28, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Rogers Corp (NYSE:ROG) reported a 6.9% increase in sales year-over-year, reaching $216.8 million, which exceeded the midpoint of their guidance. Adjusted EBITDA increased to $38 million, representing 17.3% of sales, indicating improved profitability. The company expects a strong third quarter with sales projected to increase by 10% year-over-year, driven by growth across all end markets. Rogers Corp (NYSE:ROG) is making significant progress with new products in their R&D pipeline, particularly in high-power AI and data center applications. The company has a strong balance sheet with cash and short-term investments exceeding $211 million, providing strategic flexibility. Adjusted EPS was below the midpoint of guidance due to supply chain headwinds and a one-time facility event. The company is experiencing ongoing raw material shortages and increased freight lead times, impacting operations. Aerospace and defense sales decreased slightly from last year due to variability in customer ordering patterns. The ramp-up of the new China factory resulted in a $1 million headwind in EBITDA compared to the prior year. Gross margin improvement is modest, with pressures from underutilization in the China factory and increased commodity costs. Q: Can you elaborate on the supply chain challenges and the one-time event mentioned during the quarter? Have these issues been resolved as we look into Q3? A: Ali El-Haj, President and CEO, explained that they are experiencing raw material shortages and logistics delays, particularly due to the situation in the Middle East, which has extended transit times. A small fire in one of their plants caused a temporary suspension of manufacturing, but this has been resolved without safety issues. However, freight and raw material challenges remain ongoing. Q: The Q3 guidance implies 10% top-line growth at the midpoint. Can you provide more color on the impact of underutilization in China and input cost margin pressures? A: Laura Russell, CFO, noted that the underutilization of the new China factory is expected to cause an 85 basis point headwind in Q3. Commodity costs and supply pressures will also impact margins. They are working on mitigating these through supply contracts, engineering initiatives, and potentially passing some costs to customers. Q: What are the biggest contributors to the recent acceleration in growth, and are these programs longer-term or short-term? A: Ali El-Haj highlighted that market share gains and new program wins are driving growth. The momentum is expected to continue with new design wins and improved operational performance. The growth is broad-based across industries and not considered seasonal. Q: Can you elaborate on the data center opportunities and other programs beyond microchannel coolers and curamik Power Plus? A: Ali El-Haj mentioned that they have several high-potential programs in the EV and auto markets, which are part of their strategic initiatives. These are in motion and expected to attract substantial customer interest. Q: How would you characterize your customers' willingness to move forward on various programs given the current uncertain environment? A: Ali El-Haj stated that customer interactions and program schedules remain as expected, with no major shifts in sentiment. Some customers are shifting production geographically, which benefits Rogers due to their global manufacturing capabilities. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Revenue growth of 6.9% was driven by a combination of improving market demand and specific share gains across the industrial and electronics segments. Industrial performance, the largest segment, was bolstered by market share gains in Silicon Solutions and strong rail application demand in the U.S. mass transit sector. Electronics and Communications saw double-digit growth due to a favorable mix of high-end smartphones and customer share gains in wireless infrastructure. EV market sales remained flat as improved power substrate revenues were offset by lower battery material orders, though sequential improvements suggest a bottoming out. Management attributes the broad-based growth to an agile, customer-focused organizational pivot that has shortened lead times and accelerated response to design changes. Aerospace and Defense experienced slight declines due to customer ordering variability, though commercial aerospace demand within the AMS business remained a bright spot. Q3 guidance assumes 10% year-over-year revenue growth, supported by a significant expected recovery in defense sales and continued strength in general industrial markets. Management expects adjusted EBITDA margins to reach approximately 20% in Q3, representing a 250 basis point year-over-year improvement driven by volume and cost actions. The R&D pipeline is focused on microchannel cooler technology and high-frequency circuit materials for next-generation AI server architectures and high-power data centers. Second-half EV sales are projected to strengthen as recent design wins for new programs begin to ramp up into late 2026 and early 2027. Capital expenditure for the full year 2026 is targeted between $30 million and $35 million to support strategic flexibility and innovation. A one-time facility fire event and subsequent cleanup costs impacted Q2 earnings, contributing to a total EPS headwind of more than $0.10 from various operational challenges. Supply chain disruptions, specifically raw material shortages and extended transit times from the Middle East (increasing from a range of 4 to 6 weeks to over 12 weeks in some instances), remain an ongoing challenge. The ramp-up of the new Ceramic China factory is expected to create an 85 basis point gross margin headwind in the third quarter due to underutilization. Rising commodity costs for silver and copper are pressuring margins, though management is evaluating price pass-throughs and engineering initiatives to reduce consumption. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management clarified that the growth is not seasonal but driven by market share gains and new program launches scheduled through early 2027. The growth is broad-based across all four major end markets rather than being concentrated in a single industry. The facility fire issue is fully resolved, but logistics delays and raw material tightness in copper and silver are expected to continue. Management noted that while they see 'light at the end of the tunnel' for materials, freight expenses remain a persistent headwind. The elevated rate is due to valuation allowances in specific jurisdictions based on current business performance. Management expects to work toward a lower rate in 2027 as business results improve and tax optimization strategies are implemented. Management indicated they have been very active in evaluating opportunities over the last few months, focusing on strategic fit over current market volatility. They suggested that the current market environment might provide better valuation opportunities than a year ago, with potential updates coming in the next quarter.

Rogers Corp. (ROG) came out with quarterly earnings of $0.92 per share, missing the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.34 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -7.07%. A quarter ago, it was expected that this specialty materials company would post earnings of $0.68 per share when it actually produced earnings of $0.75, delivering a surprise of +10.29%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Rogers Corp., which belongs to the Zacks Electronics - Miscellaneous Components industry, posted revenues of $216.8 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.84%. This compares to year-ago revenues of $202.8 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Rogers Corp. shares have added about 41.2% since the beginning of the year versus the S&P 500's gain of 8.3%. While Rogers Corp. has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Rogers Corp. was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.06 on $224.7 million in revenues for the coming quarter and $3.71 on $859.3 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Electronics - Miscellaneous Components is currently in the top 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Allient (ALNT), has yet to report results for the quarter ended June 2026. The results are expected to be released on August 5. This motion control product maker is expected to post quarterly earnings of $0.62 per share in its upcoming report, which represents a year-over-year change of +8.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Allient's revenues are expected to be $146.28 million, up 4.8% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Rogers Corporation (ROG) : Free Stock Analysis Report Allient Inc. (ALNT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Engineered materials manufacturer Rogers (NYSE:ROG) announced better-than-expected revenue in Q2 CY2026, with sales up 6.9% year on year to $216.8 million. On top of that, next quarter’s revenue guidance ($238 million at the midpoint) was surprisingly good and 5.6% above what analysts were expecting. Its GAAP profit of $0.76 per share was 16.9% below analysts’ consensus estimates. Is now the time to buy Rogers? Find out in our full research report. Revenue: $216.8 million vs analyst estimates of $215 million (6.9% year-on-year growth, 0.8% beat) EPS (GAAP): $0.76 vs analyst expectations of $0.92 (16.9% miss) Adjusted EBITDA: $37.6 million vs analyst estimates of $37.15 million (17.3% margin, 1.2% beat) Revenue Guidance for Q3 CY2026 is $238 million at the midpoint, above analyst estimates of $225.5 million Operating Margin: 9.2%, up from 4.2% in the same quarter last year Free Cash Flow Margin: 11.3%, up from 2.8% in the same quarter last year Market Capitalization: $2.31 billion With roots dating back to 1832, making it one of America's oldest continuously operating companies, Rogers (NYSE:ROG) designs and manufactures specialized engineered materials and components used in electric vehicles, telecommunications, renewable energy, and other high-performance applications. Reviewing a company’s long-term sales performance reveals insights into its quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. With $834.8 million in revenue over the past 12 months, Rogers is a small player in the business services space, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and numerous distribution channels. As you can see below, Rogers struggled to increase demand as its $834.8 million of sales for the trailing 12 months was close to its revenue five years ago. This shows demand was soft, a rough starting point for our analysis. Long-term growth is the most important, but within business services, a half-decade historical view may miss new innovations or demand cycles. Rogers’s annualized revenue declines of 1.6% over the last two years align with its five-year trend, suggesting its demand has consistently shrunk. This quarter, Rogers reported year-on-year revenue growth of 6.9%, and its $216.8 million of revenue exceeded Wall Street’s estimates by 0.8%. Company management is currently guiding for a 10.2% year-on-year increase in sales next quarter. Looking further ahead, sell-side analysts expect revenue to grow 8.6% over the next 12 months, an improvement versus the last two years. This projection is healthy and suggests its newer products and services will fuel better top-line performance. ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all. Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE. Rogers was profitable over the last five years but held back by its large cost base. Its average adjusted operating margin of 8.7% was weak for a business services business. Looking at the trend in its profitability, Rogers’s adjusted operating margin decreased by 2.3 percentage points over the last five years. Rogers’s performance was poor no matter how you look at it - it shows that costs were rising and it couldn’t pass them onto its customers. This quarter, Rogers generated an adjusted operating margin profit margin of 9.2%, up 2.9 percentage points year on year. This increase was a welcome development and shows it was more efficient. Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions. Sadly for Rogers, its EPS declined by 16.7% annually over the last five years while its revenue was flat. This tells us the company struggled because its fixed cost base made it difficult to adjust to choppy demand. We can take a deeper look into Rogers’s earnings to better understand the drivers of its performance. As we mentioned earlier, Rogers’s adjusted operating margin expanded this quarter but declined by 2.3 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals. Like with revenue, we analyze EPS over a more recent period because it can provide insight into an emerging theme or development for the business. For Rogers, its two-year annual EPS declines of 25.1% show it’s continued to underperform. These results were bad no matter how you slice the data. In Q2, Rogers reported EPS of $0.76, up from negative $4 in the same quarter last year. Despite growing year on year, this print missed analysts’ estimates. Over the next 12 months, Wall Street expects Rogers’s full-year EPS to grow 124% from $1.75 to $3.92. We were impressed by Rogers’s optimistic revenue guidance for next quarter, which blew past analysts’ expectations. We were also happy its revenue narrowly outperformed Wall Street’s estimates. On the other hand, its EPS missed. Zooming out, we think this was a mixed quarter. The stock remained flat at $119.14 immediately following the results. So should you invest in Rogers right now? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it’s free.

Net sales of $216.8 million increased 6.9% year-over-year (YoY) Gross margin of 32.5% increased 90 basis points YoY Net income of $13.6 million, versus a $73.6 million net loss in the prior year period1 Adjusted EBITDA of $37.6 million increased by $13.7 million YoY Diluted earnings per share of $0.76, versus a loss per share of $4.00 in the prior year period1 Adjusted earnings per share of $0.92 increased by $0.58 YoY CHANDLER, Ariz., July 28, 2026--(BUSINESS WIRE)--Rogers Corporation (NYSE:ROG) today announced financial results for the second quarter of 2026. "We delivered another quarter of solid revenue growth, with sales increasing nearly 7% year over year, driven by improving customer demand and progress in our commercial initiatives," stated Ali El-Haj, Rogers' President and CEO. "Compared to the prior year adjusted EPS improved significantly and EBITDA margin expanded by 550 basis points, despite supply chain challenges. Overall, these results reflect our continuing focus on improving operating performance, and positioning Rogers for sustainable long-term growth." "Looking ahead, we are encouraged by continued progress with new product initiatives and increased customer activity levels. These developments and the positive outlook in many of our end markets are resulting in an expectation of continued year-over-year improvement in all financial metrics in the third quarter. We remain focused on both our customers and on enhancing our operational execution to drive sustained momentum through the remainder of the year." Financial Overview Q2 2026 Summary of Results Net sales of $216.8 million increased 6.9%, or $14.0 million, versus the second quarter of 2025. The higher sales were concentrated primarily in the industrial, and electronics and communications end markets. Currency exchange rates favorably affected net sales in the second quarter of 2026 by $5.3 million compared to the prior year. GAAP earnings per diluted share were $0.76 compared to a loss per share of $(4.00) in Q2 2025. The prior year period included non-cash impairment charges of $71.8 million and $4.3 million of restructuring expenses. On an adjusted basis, earnings were $0.92 per diluted share compared to earnings of $0.34 per diluted share in the second quarter of 2025. The improvement in adjusted earnings resulted from higher sales and gross margin and lower operating expenses. Second quarter ending cash and cash equivalents were $181.4 million and short-term investments were $30.0 million. These balances together increased by $15.6 million compared to the prior quarter. Net cash provided by operating activities was $24.4 million and capital expenditures were $6.1 million. Financial Outlook Conference Call and Additional Information A conference call to discuss the results for the second quarter will take place today, Tuesday, July 28, 2026 at 5:00 pm ET. A live webcast of the event and the accompanying presentation can be accessed on the Rogers Corporation website at https://www.rogerscorp.com/investors. About Rogers Corporation Rogers Corporation (NYSE:ROG) is a global leader in engineered materials to power, protect and connect our world. Rogers delivers innovative solutions to help our customers solve their toughest material challenges. Rogers’ advanced electronic and elastomeric materials are used in applications for EV/HEV, automotive safety and radar systems, mobile devices, renewable energy, wireless infrastructure, energy-efficient motor drives, industrial equipment and more. Headquartered in Chandler, Arizona, Rogers operates manufacturing facilities in the United States (U.S.), Asia and Europe, with sales offices worldwide. Safe Harbor Statement Statements included in this release that are not a description of historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are generally accompanied by words or phrases such as "anticipate," "assume," "believe," "could," "estimate," "expect," "foresee," "goal," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "seek," "target" or similar expressions that convey uncertainty as to the future events or outcomes. Forward-looking statements are based on assumptions and beliefs that we believe to be reasonable; however, assumed facts almost always vary from actual results, and the differences between assumed facts and actual results could be material depending upon the circumstances. Where we express an expectation or belief as to future results, that expectation or belief is expressed in good faith and based on assumptions believed to have a reasonable basis. We cannot assure you, however, that the stated expectation or belief will occur or be achieved or accomplished. This release contains forward-looking statements regarding our plans, objectives, outlook, goals, strategies, future events, future net sales or performance, capital expenditures, future restructuring, plans or intentions relating to expansions, business trends and other information that is not historical information. All forward-looking statements are based upon information available to us on the date of this release and are subject to risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to differ materially from those indicated by the forward-looking statements. Other risks and uncertainties that could cause such results to differ include the following, without limitation: failure to capitalize on, volatility within, or other adverse changes with respect to growth opportunities, such as delays in adoption or implementation of new technologies; uncertain business, economic and political conditions in the U.S. and abroad, particularly in China, Germany, England, Belgium, South Korea and Hungary, where we maintain significant manufacturing, sales or administrative operations; the global trade policy dynamics between nations reflected in trade agreement negotiations, imposition of tariffs and other trade restrictions, as well as the potential for global supply chain decoupling; fluctuations in foreign currency exchange rates; our ability to develop innovative products and the extent to which they are incorporated into end-user products and systems that achieve commercial success; the ability and willingness of our sole or limited source suppliers to deliver certain key raw materials, including commodities, to us in a timely and cost-effective manner; business interruptions due to catastrophes or other similar events, such as natural disasters, war, terrorism or public health crises; the impact of sanctions, export controls and other foreign asset or investment restrictions; failure to realize, or delays in the realization of anticipated benefits of acquisitions and divestitures due to, among other things, the existence of unknown liabilities or difficulty integrating acquired businesses; our ability to attract and retain management and skilled technical personnel; our ability to protect our proprietary technology from infringement by third parties and/or allegations that our technology infringes third party rights; changes in effective tax rates or tax laws and regulations in the jurisdictions in which we operate; failure to comply with financial and restrictive covenants in our credit agreement or restrictions on our operational and financial flexibility due to such covenants; the outcome of ongoing and future litigation, including our asbestos-related product liability litigation; changes in environmental laws and regulations applicable to our business; and disruptions in, or breaches of, our information technology systems. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the Company. Our forward-looking statements are expressly qualified by these cautionary statements, which you should consider carefully. For additional information about the risks, uncertainties and other factors that may affect our business, please see our most recent annual report on Form 10-K and any subsequent reports filed with the Securities and Exchange Commission, including quarterly reports on Form 10-Q. Rogers Corporation assumes no responsibility to update or revise any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law. (Financial statements follow) Reconciliation of non-GAAP financial measures to the comparable GAAP measures Non-GAAP Financial Measures: This earnings release includes the following financial measures that are not presented in accordance with generally accepted accounting principles in the United States of America ("GAAP"): (1) Adjusted earnings per diluted share, which the Company defines as earnings (loss) per diluted share excluding acquisition and related integration costs, dispositions, intangible amortization, restructuring, severance, impairment and other related costs, asbestos-related charges (credits), and the related income tax effect on these items, and charges to income tax expense for valuation allowances on deferred tax assets generated in prior years, divided by adjusted weighted average shares outstanding - diluted; (2) Adjusted EBITDA, which the Company defines as net income (loss) excluding acquisition and related integration costs, dispositions, intangible amortization, severance, impairment and other related costs, asbestos-related charges (credits), interest income (expense), net, income tax (benefit) expense, depreciation of fixed assets, and equity compensation expense; (3) Adjusted EBITDA margin, which the Company defines as the percentage that results from dividing Adjusted EBITDA by total net sales; (4) Free cash flow, which the Company defines as net cash provided by operating activities less non-acquisition capital expenditures. Management believes adjusted earnings per diluted share, adjusted EBITDA and adjusted EBITDA margin are useful to investors because they allow for comparison to the Company’s performance in prior periods without the effect of items that, by their nature, tend to obscure the Company’s core operating results due to potential variability across periods based on the timing, frequency and magnitude of such items. As a result, management believes that these measures enhance the ability of investors to analyze trends in the Company’s business and evaluate the Company’s performance relative to peer companies. Management also believes free cash flow is useful to investors as an additional way of viewing the Company's liquidity and provides a more complete understanding of factors and trends affecting the Company's cash flows. However, non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation from, or as alternatives to, financial measures prepared in accordance with GAAP. In addition, these non-GAAP financial measures may differ from, and should not be compared to, similarly named measures used by other companies. Reconciliations of the differences between these non-GAAP financial measures and their most directly comparable financial measures calculated in accordance with GAAP are set forth below. The Company provides quarterly guidance for adjusted earnings per diluted share and adjusted EBITDA on a non-GAAP basis only. The forward-looking comparable GAAP measures and a reconciliation of adjusted earnings per share and adjusted EBITDA to GAAP are excluded in reliance upon the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K due to the inherent difficulty in forecasting and quantifying, without unreasonable efforts, certain reconciling items. These include, among other things, adjustments that could be made for acquisition and related integration costs, dispositions, intangible amortization, restructuring, severance, impairment and other related costs, asbestos-related charges (credits), and charges to income tax expense for valuation allowances on deferred tax assets generated in prior years, and other charges reflected in the Company’s reconciliations of historic numbers, the amount of which, based on historical experience, could be significant. The following table reconciles weighted average shares outstanding - diluted under US GAAP to adjusted weighted average shares outstanding - diluted used in the calculation of adjusted diluted EPS: View source version on businesswire.com: https://www.businesswire.com/news/home/20260728432417/en/ Contacts Investor Contact: Steve HaymorePhone: 480-917-6026Email: [email protected] Website Address: https://www.rogerscorp.com